PICAROS – Acalabrutinib RWE on 1L CLL in Spain - PICAROS

Study identifier:D8221R00003

ClinicalTrials.gov identifier:NCT05999877

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Non-interventional cohort study of patients Previously untreated or first-generation BTKi Intolerant with Chronic lymphocytic leukemia describing the first-line use of Acalabrutinib and its Real-world Outcomes in Spain: the PICAROS study

Medical condition

Chronic Lymphocytic Leukemia

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

192

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 11 Jul 2023
Estimated Primary Completion Date: 31 Dec 2026
Estimated Study Completion Date: 31 Dec 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

None

Inclusion and exclusion criteria